The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | FORTE study update: combined carfilzomib treatments in myeloma
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses updates from the FORTE trial (NCT02203643) which aims to evaluate the safety and efficacy of combined carfilzomib treatments in newly diagnosed, autologous stem cell transplant (ASCT)-eligible multiple myeloma patients. It was found that patients treated with carfilzomib combined with lenalidomide and dexamethasone who went on to have ASCT had the best outcomes, particularly in terms of progression-free survival. Flow cytometry and next-generation sequencing found that some patients achieved long-term measurable residual disease-negativity and had a reduced risk of relapse. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Honoraria and advisory board member for Amgen, Sanofi, BMS, Takeda, Janssen, Oncopeptides, Karyopharm
